Skip to Content

Nateglinide use while Breastfeeding

Drugs containing Nateglinide: Starlix

Medically reviewed on April 2, 2018

Nateglinide Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of nateglinide during breastfeeding. Nateglinide is a weak acid that is over 98% protein bound, so it is unlikely to pass into breastmilk in clinically important amounts. If nateglinide is required by the mother, it is not a reason to discontinue breastfeeding. Monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with pramlintide.[1] However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Acarbose, Glipizide, Glyburide, Insulin, Metformin, Miglitol

References

1. Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med. 2005;10:149-59. PMID: 15701580

Nateglinide Identification

Substance Name

Nateglinide

CAS Registry Number

105816-04-4

Drug Class

Hypoglycemic Agents

Administrative Information

LactMed Record Number

196

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide